• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

In vivo evaluation and Alzheimer's disease treatment outcome of siRNA loaded dual targeting drug delivery system.
Abstract To deliver drugs to treat Alzheimer's disease (AD), nanoparticles should firstly penetrate through blood brain barrier, and then target neurons. Recently, we developed an Apo A-I and NL4 dual modified nanoparticle (ANNP) to deliver beta-amyloid converting enzyme 1 (BACE1) siRNA. Although promising in vitro results were obtained, the in vivo performance was not clear. Therefore, in this study, we further evaluated the in vivo neuroprotective effect and toxicity of the ANNP/siRNA. The ANNP/siRNA was 80.6 nm with good stability when incubated with serum. The ANNP/siRNA could target both bEnd.3 and PC12 cells...
Source: Current Pharmaceutical Biotechnology - February 4, 2019 Category: Biotechnology Authors: Zhang C, Shen L, Gu Z, Liu X, Lin H Tags: Curr Pharm Biotechnol Source Type: research

Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.
Abstract RNA interference (RNAi) is an evolutionary conserved highly specific gene-silencing mechanism initiated by small interfering RNA (siRNA) molecules. Fast-paced preclinical and clinical studies helped the siRNA technology become an efficient tool for undruggable targets in different diseases including genetic diseases, viral diseases and cancer. Despite great feature of siRNAs that can down-regulate any protein in the cells, the full potential and the success of the preclinical studies could not be translated into largely successful clinical outcomes. It has become clear that the possibility of overcoming t...
Source: Current Pharmaceutical Biotechnology - March 31, 2016 Category: Biotechnology Authors: Sarisozen C, Salzano G, Torchilin VP Tags: Curr Pharm Biotechnol Source Type: research

A dual targeting drug delivery system for penetrating blood brain barrier and selectively delivering siRNA to neurons for Alzheimer's disease treatment.
CONCLUSION: In conclusion, this study preliminarily demonstrated the ApoA-I and NL4 dual modified dendrimer nanoparticles were efficient carrier for siRNA delivery to AD bearing brain. PMID: 29484985 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - February 26, 2018 Category: Biotechnology Authors: Zhang C, Gu Z, Shen L, Liu X, Lin H Tags: Curr Pharm Biotechnol Source Type: research

Current synopsis on siRNA therapeutics as a novel anti-cancer and antiviral strategy: Progress and challenges
This article stated the development in the RNA polymer and also provides some examples of their diagnostic applications and therapeutics special emphasis on the anti-cancer and antiviral strategy. Patisiran and Givosiran are the recently approved si-RNA based products available in the market.PMID:35578839 | DOI:10.2174/1389201023666220516120432
Source: Current Pharmaceutical Biotechnology - May 17, 2022 Category: Biotechnology Authors: Sanjay Sharma Rupesh K Gautam Abhishek Kanugo Dinesh Kumar Mishra Mohammad Amjad Kamal Source Type: research

Lipid-based Vehicles for siRNA Delivery in Biomedical Field.
Abstract Genetic drugs have aroused much attention in the past twenty years. RNA interference (RNAi) offers novel insights into discovering potential gene functions and therapies targeting genetic diseases. Small interference RNA (siRNA), typically 21-23 nucleotides in length, can specifically degrade complementary mRNA. However, targeted delivery and controlled release of siRNA remain a great challenge. Considering the vast number of drug carriers, when compared with viral vectors, non-viral ones show reduced cytotoxicity and low production cost. Especially, lipid-based vehicles are more promising due to their hi...
Source: Current Pharmaceutical Biotechnology - September 23, 2019 Category: Biotechnology Authors: Li T, Huang L, Yang M Tags: Curr Pharm Biotechnol Source Type: research

Recent advances in siRNA delivery systems for prostate cancer therapy
Curr Pharm Biotechnol. 2021 Jun 15. doi: 10.2174/1389201022666210615123211. Online ahead of print.ABSTRACTThe critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle-based siRNA therapeutics. The main challenges to siRNA-based therapeutics becoming a new paradigm in the treatment of prostate cancer stem from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical trans...
Source: Current Pharmaceutical Biotechnology - June 16, 2021 Category: Biotechnology Authors: Shahin Aghamiri Pourya Raee Shiva Shahmohamadnejad Sasan Shabani Jaber Ghorbani Marzieh Sameni Mohammad Taha Ebrahimi Source Type: research

Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy.
In conclusion, the siRNA-based gene silencing drug will gain an important position for treating human diseases if we can solve the gap between ideal and reality. PMID: 26511977 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - October 29, 2015 Category: Biotechnology Authors: Wu D, Han H, Xing Z, Zhang J, Li L, Shi W, Li Q Tags: Curr Pharm Biotechnol Source Type: research

The combination of baicalin with knockdown of miR148a gene suppresses cell viability and proliferation and induces the apoptosis and autophagy of human glioblastoma multiforme T98G and U87MG cells
CONCLUSION: The siRNA-induced miR148a mRNA knockdown in combination with baicalin may offer a novel therapeutic strategy to more effective control the growth of human GBM cells. Thus, knockdown of this gene in combination with baicalin inhibits proliferation (cell cycle arrest in S phase in T98G but not in U87MG cells), induces apoptosis and regulates autophagy in T98G and U87MG cells, but further studies urgently needed to confirm a positive phenomenon for the treatment of GBM.PMID:35761505 | DOI:10.2174/1389201023666220627144100
Source: Current Pharmaceutical Biotechnology - June 28, 2022 Category: Biotechnology Authors: Monika Paul-Samojedny Emilia Liduk Ma łgorzata Kowalczyk Paulina Borkowska Aleksandra Zieli ńska Renata Suchanek-Raif Jan Kowalski Source Type: research

Pages: 1  2